9 May 2023 - AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib mesylate in the treatment of amyotrophic lateral sclerosis, meaning that the information and materials submitted by AB Science in response to the Notice of Deficiency previously issued by Health Canada have been screened and found acceptable for the new drug submission to resume. 

This letter is an important step in the procedure and effectively marks the restart date of the application’s review by Health Canada. Indeed, once the Response to a Notice of Deficiency is screened and found acceptable for scientific review, a new review period begins immediately.

Read AB Science press release